LRA | Jotup

Xtrackers by DWS Launches its First Active ETF: NRES

Retrieved on:

Tuesday, February 27, 2024

DWS, one of the world's leading asset managers, announced today the listing of its first actively-managed exchange-traded fund (ETF), the Xtrackers RREEF Global Natural Resources ETF (NASDAQ: NRES) (the “Fund”).

Key Points:

DWS, one of the world's leading asset managers, announced today the listing of its first actively-managed exchange-traded fund (ETF), the Xtrackers RREEF Global Natural Resources ETF (NASDAQ: NRES) (the “Fund”).
For DWS, this listing marks its entry into the fast-growing actively managed ETF market in the US1.
DWS' robust Alternatives platform has a 50-year history of active investing for institutional, corporate, and sovereign clients worldwide.
Globally, Xtrackers by DWS is a large and established provider of high-quality exchange traded funds (ETFs) and exchange traded commodities (ETCs).

Lupus Research Alliance Announces Recipients of the Lupus Mechanisms and Targets Award

Retrieved on:

Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).

Key Points:

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).
The development of targeted treatments is hindered by an incomplete understanding of lupus and its devastating complications.
These seven talented investigators will identify targets for new treatments and test novel therapeutic avenues to revolutionize the field and improve the lives of individuals with lupus.
Surgical biopsies of the kidneys are often needed to diagnose lupus nephritis (LN), kidney inflammation caused by lupus that can result in severe and sometimes life-threatening organ damage.

Re-engineering Immune Cells Opens Door to Promising Therapy for Lupus Kidney Inflammation

Retrieved on:

Tuesday, February 6, 2024

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Research featured in Nature Communications highlights a novel approach that re-engineers a person's own immune cells to suppress the overactive immune system that occurs in lupus nephritis, a serious and potentially life-threatening inflammation of the kidneys. With funding in part from the Lupus Research Alliance (LRA), associate professor Joshua Ooi, Ph.D. and his team at the Centre for Inflammatory Disease, Monash Health in Australia, developed an innovative method that could enable multiple targeted therapies not only for lupus but other autoimmune diseases as well.

Key Points:

T cells direct the immune system's response to potential threats by identifying and attacking harmful invaders like viruses and bacteria.
In healthy individuals, a specific type of T cells called T regulatory cells (Tregs) prevent the immune system from continuing to react once an infection is cleared.
Earlier LRA funding allowed my team to pursue the idea that patients' immune cells could be engineered to correct immune dysfunction.
The Lupus Innovation Award then gave us the ability to test the effectiveness of these patient-derived engineered cells in a model of disease."

Lupus Research Alliance 2023 Dr. William E. Paul Distinguished Innovator Award Granted to Yale School of Medicine Researcher Akiko Iwasaki, Ph.D.

Retrieved on:

Tuesday, January 30, 2024

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to grant the 2023 Dr. William E. Paul Distinguished Innovator Award (DIA) to Akiko Iwasaki, Ph.D., Sterling Professor of Immunobiology at the Yale School of Medicine. Dr. Iwasaki will investigate a possible cause of lupus – remnants of ancient viruses that have been integrated into our genome called endogenous retroviruses. The DIA provides investigators up to $1 million over four years to explore bold, paradigm-shifting ideas that could lead to groundbreaking discoveries in lupus research.

Key Points:

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to grant the 2023 Dr. William E. Paul Distinguished Innovator Award (DIA) to Akiko Iwasaki , Ph.D., Sterling Professor of Immunobiology at the Yale School of Medicine.
Dr. Iwasaki will investigate a possible cause of lupus – remnants of ancient viruses that have been integrated into our genome called endogenous retroviruses.
The DIA provides investigators up to $1 million over four years to explore bold, paradigm-shifting ideas that could lead to groundbreaking discoveries in lupus research.
With this award, we will probe the link between the immune system reacting to viruses within us as a possible trigger of lupus disease," commented Dr. Iwasaki.

NASA Science, Astrobotic Peregrine Mission One Concludes

Retrieved on:

Friday, January 19, 2024

Multimedia, Science, LRA, Spacecraft, NASA Headquarters, Peregrine, CLPS, NASA, EST, Commercial Lunar Payload Services, Science Mission Directorate, Moon, Astrobotic Technology, Artemis, Communications satellite

After 10 days and 13 hours in space, Astrobotic's Peregrine Mission One made a controlled re-entry on Earth over open water in the South Pacific at approximately 4:04 p.m. EST on Jan. 18.

Key Points:

After 10 days and 13 hours in space, Astrobotic's Peregrine Mission One made a controlled re-entry on Earth over open water in the South Pacific at approximately 4:04 p.m. EST on Jan. 18.
There are seven additional CLPS deliveries awarded to multiple American companies, with more awards expected this year and for years to come.
Following a successful launch and separation from the rocket on Jan. 8, the spacecraft experienced a propulsion issue preventing Peregrine from softly landing on the Moon.
"Astrobotic's Peregrine mission provided an invaluable opportunity to test our science and instruments in space, optimizing our process for collecting data and providing a benchmark for future missions," said Nicola Fox, associate administrator for NASA's Science Mission Directorate at NASA Headquarters in Washington.

AAC's Smart Car Super-Sensing Solutions Unveiled at CES 2024, Accelerating Multimodal Interaction in Smart Cockpits

Retrieved on:

Friday, January 12, 2024

Noise, Sound, Multimedia, Vibration, Knowledge, Car, VFW, Intelligence, Perception, AAC, Electronics, Hearing, AI, Algorithm, MEMS, Exhibition, PSS, LRA, ECall, NVH, RANC, CES, System, Human, Light, Friction, AEC, Immersion

The digitized world constructed by AI is revolutionizing every industry, including smart automobiles, which are a crucial component of this exhibition.

Key Points:

The digitized world constructed by AI is revolutionizing every industry, including smart automobiles, which are a crucial component of this exhibition.
At CES, AAC introduced an integrated, all-encompassing, precise, real-time, and immersive full-stack in-car solution, accelerating the future development of intelligent cockpit multimodal interaction.
This supports the upgrade of true multi-channel in-car audio experiences, delivering comprehensive innovation with immersive, enveloping, and multi-dimensional sensations.
The booth of PSS (a provider of car audio system solutions), showcased the car-specific ultra-slim speaker USS 3060.

Lara Announces Board and Management Changes

Retrieved on:

Monday, January 8, 2024

Nevsun Resources, Reservoir, Mining, Freeport-McMoRan, Planalto, LRA, Cardiff University, JV

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2024) - Lara Exploration Ltd. (TSXV: LRA) ("Lara") is pleased to announce the appointment of Simon Ingram as President, CEO, and a Director of the Company, with Miles Thompson remaining in his role as Chairman.

Key Points:

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2024) - Lara Exploration Ltd. (TSXV: LRA) ("Lara") is pleased to announce the appointment of Simon Ingram as President, CEO, and a Director of the Company, with Miles Thompson remaining in his role as Chairman.
Miles Thompson commented: "On behalf of us all at Lara, I'd like to welcome Simon to the team, we very much look forward to working with him again.
The Planalto Copper-Gold discovery in the Carajás of Brazil is now back 100%-owned, and we see a great opportunity to create value for shareholders by moving it through the next development stages."
Simon Ingram is a senior international executive with strong technical and public company leadership experience, which he gained during over 25 years working globally in natural resource industries.

Nuclear Regulatory Commission Accepts PG&E's Diablo Canyon Power Plant License Renewal Application, Allows Both Units to Continue Operating Past Current Licenses

Retrieved on:

Tuesday, December 19, 2023

The Electric Company, LRA, PG&E, DCPP, NRC, Diablo Canyon Power Plant, Electricity, Nuclear Regulatory Commission, Renewable energy

AVILA BEACH, Calif., Dec. 19, 2023 /PRNewswire/ -- The federal Nuclear Regulatory Commission (NRC) determined today that Pacific Gas and Electric Company's (PG&E) License Renewal Application (LRA) for extended operations of Diablo Canyon Power Plant (DCPP) is sufficient for its review. The NRC's determination of sufficiency now allows PG&E to continue operating Units 1 and 2 at DCPP past their current licenses (2024 and 2025, respectively), while the LRA is under review.

Key Points:

AVILA BEACH, Calif., Dec. 19, 2023 /PRNewswire/ -- The federal Nuclear Regulatory Commission (NRC) determined today that Pacific Gas and Electric Company's (PG&E) License Renewal Application (LRA) for extended operations of Diablo Canyon Power Plant (DCPP) is sufficient for its review.
The NRC's determination of sufficiency now allows PG&E to continue operating Units 1 and 2 at DCPP past their current licenses (2024 and 2025, respectively), while the LRA is under review.
"We are grateful for the opportunity to continue providing homes and businesses across California with safe, clean, and affordable power."
More information about the license renewal process can be found at the NRC's website: Reactor License Renewal | NRC.gov

Lupus Research Alliance Gala Raises Millions for Research to Transform Treatment

Retrieved on:

Tuesday, November 21, 2023

NEW YORK, Nov. 21, 2023 /PRNewswire/ -- This year's Lupus Research Alliance (LRA) Breaking Through Gala raised $2 million for lupus research and brought the hope of tremendous progress that's improving lupus treatment while driving to a cure. The annual celebration began with a powerhouse performance and moving tribute to lupus warriors by multi-talented pianist, composer, producer, and Sony Music recording artist Chloe Flower. Emmy Award-winning TV Host and Executive Producer, Tamron Hall, brought her refreshing and relatable voice to emcee the night's program with warmth and compassion.

Key Points:

The annual celebration began with a powerhouse performance and moving tribute to lupus warriors by multi-talented pianist, composer, producer, and Sony Music recording artist Chloe Flower.
"Lupus is a complex autoimmune disease that can take years to get diagnosed and disproportionately affects women of color in prevalence and severity.
Being here to help raise awareness and funds for the finest research is how we can best help improve the lives of people with lupus," explained Hall.
A star of the event, the iconic Empire State Building, brightened the city Sunday night, highlighting the importance of lupus research by lighting up NYC's skyline in the colors of lupus research awareness – purple and red.

LRA Highlights Groundbreaking Lupus Research at ACR Convergence 2023

Retrieved on:

Monday, November 6, 2023

SLE, American College, Lupus Research Alliance, Genotype, Skin, Context, Gene, Kidney, Research, Lupus, LRA, American College of Rheumatology, Brain, Therapy, ACR, SAN, Pharmaceutical industry

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- The Lupus Research Alliance (LRA), the largest non-governmental non-profit funder of lupus research worldwide, is pleased to announce results from more than 30 studies supported by the LRA and its clinical research affiliate Lupus Therapeutics will be presented at ACR Convergence 2023, the annual meeting of the American College of Rheumatology.

Key Points:

This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of, the American College of Rheumatology.
SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- The Lupus Research Alliance (LRA), the largest non-governmental non-profit funder of lupus research worldwide, is pleased to announce results from more than 30 studies supported by the LRA and its clinical research affiliate Lupus Therapeutics will be presented at ACR Convergence 2023, the annual meeting of the American College of Rheumatology.
Studies will represent the full continuum of research that the LRA and Lupus Therapeutics support, from innovative foundational research to lupus clinical trials evaluating potential new treatments.
LRA-funded investigators will be presenting their recent breakthroughs across a broad spectrum of lupus research, including the impact of lupus on various organs such as the skin, kidney, and brain, the contribution of the gut microbiome to lupus, dysregulation of a variety of immune cell types underlying lupus, and more.